DSE/ACMELAB (DSE/ACMELAB)

Dhaka Stock Exchange: DSE/ACMELAB · BDT

BDT 78.0

+0.50 (+0.6%)· Recorded snapshot

Market cap	16.5B
Revenue (ttm)	40B
Net income (ttm)	2.7B
EPS (ttm)	BDT 12.6
Shares out	211.6M
P/E (trailing)	6.2x
Dividend	BDT 3.50 (4.49%)
Volume	130,481
Beta	0.12

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 40B
Net income (ttm): 2.7B
EPS (ttm): BDT 12.6
P/E (trailing): 6.2x
Market cap: 16.5B

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-29 13:30 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/E6.2

P25 n/aP50 n/aP75 n/a

ROE9.9

P25 n/aP50 n/aP75 n/a

ROIC10.5

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DSE/ACMELAB indicators

Market & fundamental data

Available fields

235

Groups with data

Currency

BDT

Showing 235 of 235 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	BDT
Country	Bangladesh
Country code	BD
Earnings date	2026-11-03
Employees	9,025
Employees change	-276
Employees growth	-2.97%
Enterprise value	BDT 36.5B
Exchange	Dhaka Stock Exchange
Financial currency	BDT
Financial report date	2026-03-31
First seen	2026-05-10
Fiscal year end	June
Founded	1954
Industry	Pharmaceutical Preparations
Is primary listing	Yes
ISIN number	BD0491ACME00
Last earnings date	2026-04-29
Last refreshed	2026-10-29
Market cap	BDT 16.5B
Next earnings date	2026-11-03
Price	BDT 78.00
Price currency	BDT
SIC code	2834
Stock price date	2026-10-28
Symbol	dse/ACMELAB
Website	https://www.acmeglobal.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Average P/E ratio (10Y)	10.7x
Average P/E ratio (3Y)	6.74x
Average P/E ratio (5Y)	7.92x
Earnings yield	16.15%
EV/Earnings	13.67x
EV/EBIT	5.44x
EV/EBITDA	4.07x
EV/FCF	11.5x
EV/Sales	0.91x
FCF / EV yield	8.7%
FCF yield	19.21%
Graham number	193.63522
Graham upside	148.25%
Industry P/E	9.77x
Lynch fair value	BDT 153.02
Lynch upside	96.18%
P/B ratio	0.59x
P/E ratio	6.19x
P/FCF ratio	5.21x
P/OCF ratio	2.88x
P/S ratio	0.41x
Price / tangible book value	0.59x
Price/EBITDA ratio	1.85x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	16.75%
EBITDA margin	22.3%
Effective tax rate	25.37%
FCF margin	7.92%
Gross margin	41.55%
Operating margin	16.75%
Pretax margin	8.92%
Profit margin	6.66%
Profit per employee	BDT 295,383
Revenue per employee	BDT 4.4M
ROA	7.1%
ROA (5Y)	6.32%
ROCE	17.81%
ROE	9.86%
ROE (5Y)	9.58%
ROIC	10.47%
ROIC (5Y)	9.17%
Tax / revenue	2.26%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	10.93%
EPS growth (Q)	17.44%
EPS growth (QoQ)	6.45%
EPS growth 10Y	7.49%
EPS growth 3Y	6.58%
EPS growth 5Y	12.16%
FCF growth (QoQ)	41.32%
Gross profit growth	14.15%
Gross profit growth (Q)	8.04%
Gross profit growth 3Y	17.3%
Gross profit growth 5Y	16.4%
Net income growth	10.93%
Net income growth (Q)	17.29%
Net income growth (QoQ)	6.4%
Net income growth 3Y	6.58%
Net income growth 5Y	12.15%
OCF growth	140.86%
OCF growth (Q)	734.74%
OCF growth (QoQ)	49.74%
OCF growth 10Y	16.04%
OCF growth 3Y	58.16%
OCF growth 5Y	24.73%
Operating income growth	7.81%
Operating income growth (Q)	-6.95%
Operating income growth 3Y	15.96%
Operating income growth 5Y	13.03%
Revenue growth	15.25%
Revenue growth (Q)	12.84%
Revenue growth (QoQ)	2.98%
Revenue growth 10Y	12.44%
Revenue growth 3Y	15.68%
Revenue growth 5Y	14.51%

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	BDT -2.6B
Depreciation and amortization	BDT 2.2B
EBIT	BDT 6.7B
EBITDA	BDT 8.9B
EPS	BDT 12.60
FCF per share	BDT 14.98
Financing cash flow	BDT -2.2B
Free cash flow	BDT 3.2B
Gross profit	BDT 16.6B
Income taxes	BDT 906.3M
Investing cash flow	BDT -2.6B
Net borrowing	BDT -1.4B
Net cash flow	BDT 1B
Net income	BDT 2.7B
Operating income	BDT 6.7B
Revenue	BDT 40B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.81
Book value per share	BDT 132.27
Debt / EBITDA	2.65
Debt / equity	0.85
Debt / FCF	7.49
Interest coverage	2.14
Long-term assets	BDT 33.3B
Long-term liabilities	BDT 9.7B
Net cash (debt)	BDT -19.9B
Net cash / market cap	-120.87%
Net debt / EBITDA	2.23
Net debt / equity	0.71
Net debt / FCF	6.29
Piotroski F-Score	6
Property, plant and equipment	BDT 33.2B
Shareholders' equity	BDT 28B
Tangible book value	BDT 27.9B
Tangible book value per share	BDT 131.79
Total assets	BDT 59.5B
Total cash	BDT 3.8B
Total debt	BDT 23.8B
Total liabilities	BDT 31.5B
WACC	7.83%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.68
Current assets	BDT 26.2B
Current liabilities	BDT 21.9B
Current ratio	1.2
Inventory turnover	1.86
Net working capital	BDT 17.2B
Quick ratio	0.34
Working capital	BDT 4.3B
Working capital turnover	12.86

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend growth	14.29%
Dividend growth (3Y)	6.62%
Dividend growth (5Y)	9.86%
Dividend growth years	0
Dividend payment date	2027-01-21
Dividend payment years	11
Dividend payout frequency	Annual
Dividend per share	BDT 3.50
Dividend yield	4.49%
Ex-dividend date	2026-11-19
FCF payout ratio	26.7%
Last dividend	BDT 4.00
Payout ratio	27.8%
Shareholder yield	4.49%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-20.57%
10Y return CAGR	1.28%
10Y total return	13.51%
150-day SMA	BDT 79.02
1D price change	0.65%
1M price change	-1.27%
1M total return	-1.27%
1W price change	1.43%
1W total return	1.43%
1Y price change	3.59%
1Y return CAGR	8.73%
1Y total return	8.73%
20-day SMA	BDT 77.49
200-day SMA	BDT 78.06
3M price change	-5.57%
3M total return	-5.57%
3Y price change	-8.24%
3Y return CAGR	1.63%
3Y total return	4.97%
50-day SMA	BDT 78.39
50-day SMA vs 200-day SMA	50over200
52-week high	BDT 88.70
52-week high date	2026-07-06
52-week low	BDT 68.60
52-week low date	2025-12-21
5Y price change	-11.76%
5Y return CAGR	1.46%
5Y total return	7.53%
6M price change	3.31%
6M total return	3.31%
All-time high	BDT 124.80
All-time high date	2016-06-12
All-time low	BDT 54.20
All-time low date	2020-03-18
Average true range (ATR)	BDT 1.14
Average volume	110.6K
Beta (1Y)	0.24
Beta (2Y)	0.03
Beta (5Y)	0.12
Change from 52-week high	-12.06%
Change from 52-week low	13.7%
Change from all-time high	-37.5%
Change from all-time low	43.91%
Change from open	0.13%
Day's gap	0.52%
Dollar volume	BDT 10.2M
High price	BDT 78.10
Low price	BDT 77.30
Monthly RSI	50.18
Open price	BDT 77.90
Position in 52-week range	87.5%
Previous close	BDT 77.50
Price vs 150-day SMA	-1.29%
Price vs 20-day SMA	0.66%
Price vs 200-day SMA	-0.08%
Price vs 50-day SMA	-0.5%
Relative volume	1.18
RSI	51.97
Sharpe ratio	0.16
Sharpe ratio (3Y)	-0
Sharpe ratio (5Y)	0.13
Sortino ratio	0.62
Sortino ratio (3Y)	0.31
Sortino ratio (5Y)	0.5
Volume	130.5K
Weekly RSI	0
YTD price change	10.01%
YTD total return	10.01%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	137.8M
Shares change (QoQ)	-0.05%
Shares held by insiders	34.86%
Shares held by institutions	7.51%
Shares outstanding	211.6M

Deeper analysis on DSE/ACMELAB

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DSE/ACMELAB report

Is a complete DSE/ACMELAB research report available?

No complete published report is available for dse/ACMELAB (DSE/ACMELAB) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

DSE/ACMELAB (DSE/ACMELAB)

Price

Financial snapshot

Fair-value bridge

Latest news · DSE/ACMELAB

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DSE/ACMELAB indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DSE/ACMELAB

Frequently asked questions